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Abstract Transcriptional activation of the hepatic phospho-
enolpyruvate carboxykinase (PEPCK) gene at birth is critical
since PEPCK appearance initiates hepatic gluconeogenesis. A
delayed appearance results in hypoglycemia, while a premature
appearance results in neonatal diabetes, both are incompatible
with sustaining life. Experiments using transgenic mice and
transfected hepatoma cells suggest that both repression and
activation underlie the correct onset of hepatic PEPCK gene
transcription. In transgenic mice, transgenes driven by the
proximal PEPCK promoter are prematurely expressed in the
fetal liver and over-expressed in the neonatal liver, indicating
that sequences upstream of the proximal promoter restrain
perinatal expression. In Hepa1c1c7 cells, which mimic the fetal
liver, the proximal PEPCK promoter (597 bp) exhibited a 3.5^
10-fold higher activity than longer promoters. Repression of the
longer promoter (2000 bp) was diminished upon deletion of the
sequence spanning positions 3840 to 31116 which contains a
PPAR/RXR recognition element. The intact 2000 bp PEPCK
promoter could be markedly activated by co-transfecting the
transcription factor HNF-1 together with C/EBP. It could be
repressed by co-transfection with RXRK and adding PPARK
relieved this inhibition.
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1. Introduction
The liver plays a major role in mammalian glucose homeo-
stasis by providing glucose to the blood via gluconeogenesis.
This function becomes critical after the detachment of the
newborn from the maternal supply of glucose at birth. Phos-
phoenolpyruvate carboxykinase (PEPCK) catalyzes the limit-
ing step of gluconeogenesis. In fact, it regulates gluconeogen-
esis since its activity readily changes in response to a variety of
hormonal and dietary conditions. These changes are the con-
sequences of modulations of PEPCK gene transcription (for
reviews see [1,2]).
As a result of the activation of hepatic PEPCK gene tran-
scription [3], the appearance of hepatic PEPCK at birth ini-
tiates gluconeogenesis. The timing of this appearance is crit-
ical, since delaying it results in hypoglycemia, while its
premature appearance results in neonatal diabetes, both of
which are incompatible with sustaining life (for review see
[4]). Thus, the activation of hepatic PEPCK gene transcription
at birth and the prevention of its premature activation prior
to birth are equally important.
The PEPCK gene is expressed in three tissues, in the glu-
coneogenic liver and kidney and in the glyceroneogenic adi-
pose tissue. Of these, hepatic expression of PEPCK is most
directly associated with glucose homeostasis in the blood.
The activation of PEPCK gene transcription at birth corre-
lates the late appearing transcription factors from the C/EBP
family. Studies by us and by others, in cultured hepatoma
cells and in transgenic mice, have suggested that the PEPCK
gene is a target of members of the C/EBP family for tran-
scription factors [5^8]. Its activation at birth coincides with
the abruptly increasing hepatic levels of the C/EBP family of
proteins at this time [9,10]. Knockout of the gene for C/EBPK
results in neonatal lethality with hypoglycemia, associated
with the lack of appearance of hepatic PEPCK and glucose
6-phosphatase at birth [11]. Furthermore, we have recently
demonstrated, using mice homozygous for disruption of C/
EBPL, that this activator is also associated with the develop-
mental activation of hepatic PEPCK gene transcription at
birth [12].
Although hepatic PEPCK gene transcription initiates at
birth [3], it can be activated in rat fetuses by in utero injecting
them with either cAMP [13] or agents that reduce insulin,
such as streptozotocin or anti-insulin serum [14,15]. More
recent experiments have established that these two treatments
di¡erentially induce the expression of genes encoding C/EBPK
and C/EBPL, along with activating PEPCK gene transcription
in the fetal liver [12]. Furthermore, we have shown that the
premature activation of hepatic PEPCK gene by in utero in-
jection of Bt2cAMP is considerably reduced in mice homozy-
gous for the disruption of the C/EBPK gene [12]. These data
document the involvement of C/EBP transcription factors in
the activation of hepatic PEPCK gene transcription. However,
in addition to activation, other data imply that the hepatic
gene transcription might be repressed prior to birth: (a)
PEPCK is expressed in several hepatoma cells that are poor
in C/EBPK [16,17]; (b) this factor is already expressed in the
fetal liver albeit at a low level [9,18]; (c) using PEPCK anti-
body for immunohistochemical analyses revealed that, in ad-
dition to the main three PEPCK-expressing tissues, a minimal
level of expression of the gene can be detected in many tissues
(such as the salivary glands), except the fetal liver [19]. Since
the PEPCK gene is probably transcribed at low levels in many
tissues the failure to detect any expression in the fetal liver is
surprising, suggesting that even a minimal PEPCK expression
in the fetal liver is inhibited. In this study we examine this
issue, using transgenic mice and hepatoma cell lines.
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2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM), F12 and fetal calf
serum were purchased from Biological Industries, Kibutz Beit Hae-
mek, Israel. Nytran membrane (Schleicher and Schuell) was used for
blot hybridization. Radioactive signals were quanti¢ed by phosphor-
imaging (Fujix BAS 1000, Fuji, Japan).
2.2. Animals
Lines of transgenic mice [20], containing the entire rat PEPCK
gene, in which a 465 bp fragment in the last exon was replaced by
a non-homologous counterpart 485 bp fragment from the chicken
PEPCK cDNA [21], were used in these experiments. The independent
lines of transgenic mice used, F8, M12, M9 and M16, contain the
chimera gene with 540 bp of the 5P £anking region of the PEPCK
gene (designated CRC540). Transgenic mice were detected by PCR
(polymerase chain reaction) [22] of tail DNA using the 5P and 3P
primers GGGAAAGCCTCTGCCAAGTCA and CACAGTTTT-
GAAGACTGTGTGCTC of the 485 bp chicken insert, spanning po-
sitions +4935 to +5420 of the chimera PEPCK gene. A unique HpaI
restriction site in the ampli¢ed insert was used for veri¢cation. Nine-
teen day old fetuses and 1 day old newborn mice were used in these
experiments.
2.3. Molecular probes and RNA analysis
PEPCK cDNA probe was a 1.6 kb PstI fragment [23]. The 485 bp
fragment of the chicken PEPCK cDNA (c485) and its counterpart rat
cDNA were as described previously [20]. The rpL7 cDNA for the rat
ribosomal protein L7 [24] was used to normalize RNA amounts in the
Northern blots. The analysis was as previously described [20], using
50 Wg total hepatic RNA prepared by the method of Chirgwin et al.
[25] as described [20].
2.4. Cell culture, transfection conditions and CAT assays
Hepa1c1c7 and HepG2 hepatoma cell lines were grown in the
growth medium containing a 1:1 mixture of DMEM and F12, and
10% fetal calf serum. Cells were transfected by calcium phosphate
precipitation, essentially according to Chen and Okayama [26], as
previously described [17], using 1 Wg of supercoiled plasmid and addi-
tional carrier pBS DNA (Stratagene), to make a total of 20 Wg. The
transfection e⁄ciency was monitored by including 0.1 Wg of pS16-GH
as an internal standard [27], containing the human somatotropin
(hGH) gene driven by the ribosomal protein S16 (rpS16) promoter.
The levels of hGH secreted into the medium were determined by
radioimmunoassay [27], using a commercial kit (St. Nichols, San Die-
go, CA, USA) according to the supplier’s instructions. Where indi-
cated, 1 Wg each of HNF-1K, C/EBPK and HNF-4 or peroxisome
proliferator-activated receptor (PPAR) K and retinoid X receptor
(RXR) K expression vectors were added to the transfection mix.
The percent of acetylated 14C-labeled chloramphenicol, from the
sum of acetylated and non-acetylated spots identi¢ed by autoradiog-
raphy of the TLC plates, was quanti¢ed using a phosphorimager
apparatus.
2.5. Plasmids used in transfection
The previously described plasmids 597-pck-CAT and 4800-pck-
CAT contain 597 bp and 4800 bp respectively of the rat PEPCK
promoter region fused to the CAT reporter gene [28]. The derived
plasmid 2000-pck-CAT contains 2000 bp of the PEPCK promoter
and plasmid v(840^1116) contains an internal deletion in the 2000
bp PEPCK promoter, spanning positions 3840 to 31116 of the tran-
scription start site. The deleted sequence contains PPARE (a PPAR/
RXR motif) at positions 3897 to 3997 of the transcription start site
[29]. DNA amounts of the constructs containing longer PEPCK pro-
moters than 597-pck-CAT were corrected to achieve the same number
of molecules as that of the proximal promoter (597-pck-CAT). Ex-
pression vectors encoding the liver enriched transcription factors used
in this work included: HNF-1K (also termed HNF-1) [30], C/EBPK
[16], HNF-4 [31], PPARK [32] and RXRK [33].
3. Results
In the transgenic mice used in this work the transgenes
driven by the proximal rat PEPCK promoter (540 bp) prema-
turely expressed in the fetal liver, albeit at low levels (Fig. 1).
This was in contrast to the lack of expression of the endoge-
nous PEPCK gene (Fig. 1) or to previous ¢ndings showing a
lack of expression in the fetal liver of both the endogenous
PEPCK gene and transgenes driven by 2000 bp of the rat
PEPCK promoter [20]. Furthermore, even in 1 day old new-
born mice, when both the endogenous gene and transgenes
were activated, the hepatic expression of the transgenes mark-
edly exceeded that of the endogenous gene (Fig. 1). Again,
this was in contrast to previous ¢ndings that expression of
transgenes driven by the 2000 bp PEPCK promoter did not
exceed that of the endogenous gene [20]. These results sug-
gested that sequences upstream of position 3540 of the
PEPCK gene exerted an inhibitory e¡ect on its transcription
during the perinatal period.
To further investigate this phenomenon, we utilized the
mouse hepatoma Hepa1c1c7 cell line [34] (Hepa), which
mimics the fetal liver [17]. Transient transfection experiments
with the CAT reporter gene driven by various sizes of the rat
PEPCK promoter showed (Fig. 2A) that the promoter activ-
ities decreased about 3.5- and 10-fold when their sequence
length increased from 597 bp to 2000 and 4800 bp respec-
tively. In contrast, similar analyses using the PEPCK express-
ing HepG2 human hepatoma cells (Fig. 2B) or H4IIEC3 rat
hepatoma cells (results not shown) showed that all promoters
shared similar activities regardless of size.
The existence of inhibitory sequences upstream of position
32000 has been previously documented [35]. The region be-
tween positions 32000 and 3597 of the transcription start site
has not been similarly analyzed. This region contains a
PPARE recognition site for the PPAR, which bind PPARE
as heterodimers with the RXR [29]. Internal deletion of this
sequence (within positions 31116 to 3840 of the PEPCK
gene) diminished the inhibition of the 2000 bp promoter ac-
tivity in Hepa cells (Fig. 2A), but had no e¡ect on the activity
of this promoter in HepG2 cells (Fig. 2B).
Since the deletion mutant has implicated PPARE in the
repression of PEPCK promoter activity, experiments were de-
signed to assess the role of its cognate factors in this modu-
lation. Members of the PPAR family are nuclear receptors
that form heterodimers with RXR and have been shown to
bind PPARE of the rat PEPCK promoter and stimulate its
activity in NIH3T3 cells [29]. In contrast, RXR can form
Fig. 1. Hepatic perinatal expression of PEPCK gene and transgene.
Northern blot hybridization of 50 Wg/lane of total hepatic RNA
from independent lines of transgenic mice (F8, M12, M9, M16, see
Section 2) prepared from 19 day old fetuses (Fetal) and 1 day old
neonates (Newborn). The c485 probe reveals the transgene expres-
sion (EXO) and its counterpart rat probe reveals the endogenous
PEPCK gene expression (ENDO). The ribosomal protein cDNA L7
(rpL7) monitors RNA loading.
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homodimers which, in turn, can repress the activities of var-
ious target promoters via appropriate recognition sites [36^
38]. To investigate whether RXRK could inhibit the PEPCK
promoter activity we co-transfected its expression vector ei-
ther alone or with PPARK expression vector, together with
the CAT gene driven by the 2000 bp PEPCK promoter.
Although this promoter activity was already inhibited (Fig.
2), RXRK by itself further inhibited its activity (Fig. 3).
This inhibition disappeared by adding PPARK expression vec-
tor, causing even a stimulation (U2.5) of the promoter activ-
ity. Thus, the distal PPARE in the PEPCK promoter was
capable of mediating either repression or a slight activation
of the promoter activity, depending on the cognate transcrip-
tion factors available.
Besides repression, it was evident (Fig. 1) that in the new-
born liver not only transgenes driven by the proximal pro-
moter were markedly activated, but the endogenous PEPCK
gene was activated as well. Previous evidence documented that
this activation was linked to the rise in the hepatic level of C/
EBP family of proteins because it failed to occur upon the
disruption of the C/EBP genes leading to neonatal lethality
[11,12]. Hepa cells lack liver-enriched transcription factors
such as C/EBPK and HNF-1K. We have previously shown
that these factors synergistically stimulated the proximal pro-
moter activity in these cells [17]. To investigate whether these
factors could stimulate the longer promoter activity as well we
co-transfected their expression vectors together with PEPCK-
CAT constructs driven by the longer promoters (4800 bp,
results not shown and 2000 bp, Fig. 3). The results showed
that these factors markedly stimulated the activities of the
longer promoters.
4. Discussion
Our present results demonstrate that transgenes driven by
the proximal PEPCK promoter (540 bp) exhibit temporal un-
restrained hepatic expression in the perinatal period, resulting
in premature onset of expression in the fetal liver and over-
expression in the neonatal liver. Complementary transfection
experiments in hepatoma cells have assisted us in: (a) recon-
structing the repressed activities of longer PEPCK promoters
(containing sequences upstream of position 3597 of the
PEPCK gene); (b) disclosing the role of the distal PPAR/
RXR recognition sequence which, depending on the cognate
factors, confers either repression or stimulation of the pro-
moter activity; (c) showing that the repression disappears in
the presence of speci¢c liver-enriched transcription activators.
Taken together, our ¢ndings strongly suggest that two
mechanisms regulate the correct onset of hepatic PEPCK
gene expression after birth: (a) activation of the gene expres-
sion by distinct liver-enriched transcription factors which, in
turn, appear relatively late in development; (b) prevention of
a premature onset of expression, via speci¢c regulatory se-
quences and their cognate transcription factors. The latter is
partially mediated via PPARE, which can confer repression or
activation depending on the availability of its cognate tran-
scription factors. As previously reported [29], PPARE binds
either a heterodimer comprising PPAR and RXR or a homo-
dimer of RXRK. It has been shown that when RXRK dimer-
izes to form a homodimer it inhibits, rather than activates, a
number of promoters [36^,38]. As is now evident, RXRK also
inhibits the PEPCK promoter activity when supplemented
alone. However, the co-supplemented PPARK abolishes this
inhibition and even moderately stimulates the longer pro-
moter activity. The signi¢cance in vivo of this versatile behav-
ior of PPARE lends support from the relatively late perinatal
appearance of PPARK [39]. Furthermore, intensive studies in
recent years have shown that nuclear receptors can mediate
either repression or activation of target gene expression, de-
pending on their binding to adapter molecules such as NCoR
a corepressor or NCoA a coactivator (for recent reviews see
[40,41]). In the case of the hepatic PEPCK promoter, although
the repression disappears in the presence of the heterodimer
PPAR/RXR the stimulation by these receptors is moderate.
In contrast, C/EBP together with HNF-1 markedly stimu-
late all PEPCK promoters reaching similar high levels of ac-
tivities in their presence regardless of the promoter size. This
might occur either by erasing the inhibition or, alternatively,
by excessively stimulating the longer promoters to overshad-
ow the inhibition. A synergistic stimulation by these two tran-
scription factors has been shown for the human albumin pro-
Fig. 2. E¡ect of the size of the PEPCK promoter activity in hepato-
ma cell lines. Transient transfection experiments in Hepa cells (A)
and HepG2 cells (B) with CAT reporter gene driven by various sizes
of the PEPCK promoter (597, 2000 and 4800 bp) and with a 2000
bp promoter containing an internal deletion of positions 3840 to
31116 of the transcription start site (v(840^1116)). The histograms
represent the means þ S.E.M. (indicated by the vertical lines) of
CAT activity from 3^5 independent transfection experiments for
each construct. CAT activity is expressed as percent of the activity
measured of 597-pck-CAT.
Fig. 3. Modulation of the 2000 bp PEPCK promoter in Hepa cells
by RXR, PPAR/RXR, and by HNF-1K and C/EBPK. 2000-pck-
CAT was transfected without or co-transfected with the expression
vector for RXRK alone or together with PPARK or with those for
HNF-1K together with C/EBPK. Note the larger scale (U10) for the
activation by HNF-1K and C/EBPK. For details of CAT activity see
legend to Fig. 2.
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moter as well [42]. However, the signi¢cance of these ¢ndings
in vivo is still open; the albumin gene is not dependent in vivo
on HNF-1 or on C/EBPK since it begins to be expressed in the
fetal liver preceding the hepatic expression of C/EBPK or
HNF-1K [43^45]; it is expressed in Hepa cells which fail to
express either of these transcription factors [17] ; and it is ex-
pressed in neonatal mice homozygous for the disruption of the
C/EBPK [11] or HNF-1 genes [46]. In contrast, hepatic
PEPCK gene expression is critically dependent on C/EBPK
(although not on HNF-1 [46]) since it is not expressed in
the fetal liver or in Hepa cells and the onset of its hepatic
expression in neonates is blocked in mice homozygous for the
disruption of C/EBPK gene [3,11,17]. The present ¢ndings that
transgenes driven by the proximal PEPCK promoter prema-
turely express in the fetal liver, albeit at a low level, correlate
the absence of PPARE in these transgenes. It is attractive to
propose that, in the absence of PPARE, early activation of
the transgenes by the existence of low levels of C/EBPK and
HNF-1K in the fetal liver is facilitated. A burst of the trans-
gene expression in the neonatal liver correlates the rise in the
level of C/EBPK at this age [12].
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